Valuation: Galapagos NV

Market Cap 1.55B 1.78B 1.44B 1.33B 2.51B 170B 2.53B 17.01B 6.65B 84.73B 6.69B 6.55B 281B P/E 2026 *
-11x
P/E 2027 * -8.31x
Enterprise Value -436M -502M -407M -373M -706M -47.76B -714M -4.79B -1.87B -23.88B -1.89B -1.84B -79.11B EV / Sales 2026 *
-30.6x
EV / Sales 2027 * -9.68x
Free-Float
74.64%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 12/05/2025
Director of Finance/CFO 41 07/07/2025
Chief Operating Officer - 01/06/2026
Director TitleAgeSince
Director/Board Member 63 22/10/2019
Director/Board Member 49 07/10/2024
Director/Board Member 53 12/05/2025
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 1.78B
-0.68%-0.68%-1.63%+12.86% 48.22B
+5.43%+4.10%+414.79%+513.26% 38.79B
-2.39%-6.16%+24.75%+5.09% 38.41B
+2.30%-2.64%+5.73%+59.06% 34.88B
+1.98%+3.97%+13.89%+40.90% 29.19B
-0.23%-0.01%+32.03%+120.65% 16B
-0.30%-4.57% - - 16.05B
+1.59%+0.44%+3.43%+16.80% 13.53B
-1.67%-13.32%-5.20%-38.34% 12.22B
Average +0.64%-0.61%+60.97%+91.29% 27.48B
Weighted average by Cap. +0.94%+0.21%+78.11%+111.00%

Financials

2026 *2027 *
Net sales 14.24M 16.4M 13.28M 12.2M 23.07M 1.56B 23.32M 157M 61.19M 780M 61.59M 60.24M 2.58B 46.09M 53.08M 42.97M 39.48M 74.66M 5.05B 75.48M 507M 198M 2.52B 199M 195M 8.36B
Net income -811M -934M -756M -694M -1.31B -88.81B -1.33B -8.91B -3.48B -44.4B -3.51B -3.43B -147B -238M -274M -222M -204M -385M -26.05B -389M -2.61B -1.02B -13.02B -1.03B -1.01B -43.15B
Net Debt -1.98B -2.28B -1.85B -1.7B -3.21B -217B -3.25B -21.8B -8.52B -109B -8.58B -8.39B -360B -1.99B -2.3B -1.86B -1.71B -3.23B -218B -3.26B -21.91B -8.57B -109B -8.62B -8.43B -362B
Logo Galapagos NV
Lakefront Biotherapeutics NV (formerly Galapagos NV) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics NV prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B